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I. INTRODUCTION
His face was so peaceful—quiet and peaceful. Finally, the pain from the cancer
that had metastasized from his colon had subsided. His wife knew that it was the
morphine; he was, however, so much at peace now. Fifty-seven years ago in a
faraway land, she promised him that she would not remove her wedding ring. The
pain and torture that they suffered during the Depression and the War were tests to
see if they could weather the trials and tribulations of life. After their children
moved away, they would live the last years of their lives traveling the South Pacific
to recapture their youth. They knew their children would take care of them. Their
country, for which they had sacrificed so much, would help them. Patriotism, selfreliance, and hard work: those principles defined the American way. Foolish dreams
built on a foundation of quick sand. They had spent $2,300 last year on the medicine
alone.1 They had neither a deductible nor a “real” prescription drug plan. They
could not afford the premiums. Medicare was there, but it was not enough. Pawning
the ring that she had worn for fifty-seven loving years was the only way . . . .2
1

Patricia Barry, Chasing Drugs: Many Readers Take Drastic Steps to Get Prescription
Medicine, Oct. 2003, available at http://www.aarp.org/bulletin/prescription/Articles/a2003-0929chasing_drugs.html (on file with author). Senior citizens are spending on average $2,300 a
year on prescription drugs and are trying to save money by carrying out some very dangerous
methods. Id.
2
See Barry, supra note 1. The above fictitious account is inspired by Ms. Barry’s article
that describes how a seventy-two year-old Pennsylvania woman actually sold her wedding
ring to pay for her prescription drugs. See generally Medicare Reform Carries Huge Fiscal
Toll, CHRISTIAN SCI. MONITOR, Oct. 17, 2003, available at http://www.aarp.org/bulletin/news/
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Unfortunately, the above account is one of many that are occurring every day to
senior citizens throughout the United States.3 The high cost of prescription drugs
and the depletion of social security benefits plague this country’s elderly.4
Consequently, many seniors travel across the border to Canada or to Mexico to find
cheaper prescription drugs.5 There are Americans who believe, however, that those
who go abroad for their medicine are unpatriotic.6
In recent years, international health organizations have proposed the adoption of
compulsory licensing to bring down the price of prescription drugs by allowing the
creation of generic drugs for AIDS, tuberculosis, and malaria to be used throughout
the developing world.7 In response to these concerns, the World Trade Organization
declared that member states could grant compulsory licenses to respond to the
serious epidemic that has spread throughout much of the developing world.8 India,
Brazil, and other emerging markets have developed the technology necessary to
create these generic drugs.9 Multinational pharmaceutical companies, however, wish
to block the manufacture and sale of generic versions of their brand-name drugs in
these markets because they fear that the loss of profits will adversely affect the
amount of money necessary for research and development of new drugs.10
This article will show that compulsory licensing is the best remedy for the
escalating cost of prescription drugs in the United States. Under section forty-five of
the Federal Trade Commission Act, the Federal Trade Commission (“FTC”) can
impose compulsory licensing of certain patented drugs that are necessary for the
immediate benefit of public health and welfare if the pharmaceutical patent holder
has “[used] unfair methods of competition in commerce and unfair or deceptive acts
Articles/article.htm (on file with author). This article highlights Congressional cost-benefit
analysis of the Medicare Reform Act. Id.
3

Id.

4

Id.

5

See Paul Egan, Michigan May Buy Canada Drugs; Granholm Seeks Solutions As Costs
Climb To $1 Billion State Orders Studies, DETROIT NEWS, Oct. 1, 2003, at 1B. Michigan is
studying Canadian importation proposals devised by Illinois, Minnesota, Massachusetts, and
Iowa regarding the purchase of prescription drugs from Canada. Id.
6

Barry, supra note 1, at 4.

7
The Declaration on the TRIPS Agreement and Public Health, (WT/MIN (01)/DEC/2 20
November 2001) [hereinafter Doha Declaration]. In November 2001, the World Trade
Organization met at Doha, Qatar and jointly declared that member states would issue
compulsory licenses of certain brand name drugs to drug manufacturers to create cheaper
prescription drug alternatives for victims of AIDS/HIV and other catastrophic diseases in
developing and low-income countries. Hence, this declaration has been called the “Doha
Declaration.” Id. In August 2003, the World Trade Organization met in Geneva, Switzerland
and established a plan on how the compulsory licenses would be issued to drug manufacturers
to create generic drugs for the developing world. See also Indian Pharmaceuticals: Patently
Ambitious, ECONOMIST, Sept. 6, 2003, at 56 [hereinafter, “Indian Pharmaceuticals”].
8

Doha Declaration, supra note 7, at ¶ 5(b).

9

Indian Pharmaceuticals, supra note 7, at 56.

10

Id.
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or practices in commerce.”11
This article will show that multinational
pharmaceutical companies can decrease the adverse effects of compulsory licensing
on their profit margins if they license Indian pharmaceutical companies, whose
manufacturing and labor costs are much lower than their U.S. counterparts, to create
cheaper generic drugs for American consumer consumption.
The following analysis will be divided into six main sections. Section II will
provide a historical overview of American pharmaceutical patent law and will
introduce the concept of compulsory licensing as a method to decrease the high cost
of prescription drugs for senior citizens in the United States.12 Section III will look
at the newly enacted Medicare Prescription Drug and Modernization Act, (“Medicare
Reform Act”), and state and local government plans to import cheaper brand-name
prescription drug from Canada.13 Section IV will look at the United States’
international support for compulsory licensing, as seen with the signing of the
Agreement on Trade Related Aspects of Intellectual Property Rights. Next, this
section will show that United States case law supports the implementation of
compulsory licensing when a corporation has violated antitrust laws.14 Finally, this
section will respond to arguments that have been made against compulsory
licensing.15 Section V will propose the creation of a tripartite health care
11
Federal Trade Commission Act, 15 U.S.C. § 45(a)(1), (a)(6) (2003). See Doha
Declaration, supra note 7; see also The General Council Chairperson’s Statement, World
Trade Organization, (Aug. 30, 2003), available at http://www.wto.org/english/news_e/
news03_e/trips_stat_28aug03_e.htm (detailing how compulsory licensing can provide
developing countries cheaper generic drugs if they do not have the capability to make the
medicine themselves). See generally Dora Kriparuri, Reasoned Compulsory Licensing:
Applying U.S. Antitrust’s “Rule of Reason” to TRIPS’s Compulsory Licensing Provision, 36
NEW ENG. L. REV. 669 (2002) (applying the American “Rule of Reason” in antitrust cases to
decide when to apply compulsory licensing). This article is a great resource for anyone
searching for U.S. cases that support the use of compulsory licensing against corporations that
violate antitrust laws.
12
See generally Jean O. Lanjouw, A New Global Patent Regime for Diseases: U.S. and
International Legal Issues, 16 HARV. J. L. & TECH. 85 (2002). This article provides a model
that would ensure a higher protection of patents in some parts of the world and lower patent
protection in areas where prescription drugs are needed to respond to AIDS/HIV-related
diseases. See also Kriparuri, supra note 11.
13

See Medicare Prescription Drug and Modernization Act of 2003, Pub. L. 108-173, 117
Stat. 2066 (2003) [hereinafter “Medicare Reform Act”]; see also Medicare Overhaul: How It
May Affect You, PLAIN DEALER (Cleveland), Nov. 25, 2003, at A1, A10 (explaining the
provisions of the Medicare Reform Bill as passed by the House of Representatives). See also
Egan, supra note 5, at 1B (reporting that Springfield, Massachusetts has implemented an online purchase plan this year for current and retired city employees “through CanaRx…at an
estimated annual savings of more than $4 million”). See also Tim Harper, ‘Buy Canada’
Drug Plan Sweeping U.S., TORONTO STAR, Oct. 26, 2003, at A06.
14

See Harford-Empire Co. v. United States, 323 U.S. 386 (1945); American Cyanamid Co.
v. Fed. Trade Comm’n, 363 F.2d 757 (6th Cir. 1966); United States v. Glaxo Group Ltd., 410
U.S. 52 (1973).
15

See Haochen Sun, A Wider Access to Patented Drugs Under the TRIPS Agreement, 21
B.U. INT’L L.J. 101 (2003); Stephen Barnes, Note, Pharmaceutical Patents and TRIPS: A
Comparison of India and South Africa, 91 KY. L.J. 911 (2002); Merrill Matthews, Jr., The
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commission (“Commission”) that will implement compulsory licensing in the United
States and will sponsor legislation that responds to the health care crisis in the United
States. Additionally, this section will propose that the multinational pharmaceutical
companies license patents to, and enter into outsourcing agreements with, Indian
pharmaceutical companies to reduce manufacturing costs, which will eventually
balance the profit-making interests of pharmaceutical companies with the health care
interests of the American public.16 Section VI will conclude this analysis and restate
the idea that America’s elderly deserve better treatment from their country and that
compulsory licensing and an alliance with the Indian pharmaceutical industry are
effective remedies for bringing down the high costs of prescription drugs in America.
II. HISTORICAL OVERVIEW OF AMERICAN PHARMACEUTICAL PATENTS AND
COMPULSORY LICENSING
A. Patents and the American Pharmaceutical Industry
A patent is a federally granted exclusive right to an inventor to manufacture, use,
or sell his “novel, useful, and nonobvious” invention for a fixed period of time that
begins after the patent application has been filed.17 In essence, the patent gives the
patent holder a legal monopoly over the invention because the patent prevents
anyone, other than the inventor, from using, selling, or making the invention.18
Suppose American pharmaceutical company Cosmore develops a new
cholesterol-lowering drug.19 The drug has met the “novel, useful, and nonobvious”
criteria of a patentable invention.20 From the moment of filing the application for the
patent, Cosmore will have exclusive rights to the drug for twenty years.21 This
means that only Cosmore can profit from the manufacture, advertising, and sale of
the drug for the next twenty years.22 As a result, no other company or inventor can
attempt to manufacture and sell the same drug for the life of the patent without the
permission of Cosmore, the exclusive patent holder.23 Therefore, patents are an
important factor for progress and innovation in this country.

Ethical Dilemmas of Prescription Drug Reimportation, IDEAS: INNOVATIVE
TODAY’S POLICY DEBATES, May 2003, available at http://www.ipi.org.
16

INSIGHTS ON

Indian Pharmaceuticals, supra note 7.

17

35 U.S.C. §§ 101-103 (2003). See also Myra Hart, Howard Zaharoff & Joshua Lerner,
The Protection of Intellectual Property in the United States, HARV. BUS. SCH. No. 9-897-046
(Rev. Mar. 1998). Utility and plant patents have a twenty-year life span and design patents
have a fourteen-year life span. Id. at 5. The inventor becomes the right holder or patent
holder once he gets patent. Id.
18

Hart, Zaharoff & Lerner, supra note 17.

19

Hypothetical facts created by author.

20

35 USC §§ 101-103 (2003). See generally Hart, Zaharoff & Lerner, supra note 17.

21

Hart, Zaharoff & Lerner, supra note 17, at 5.

22

See, e.g., Harper, supra note 13, at A06.

23

Hart, Zaharoff & Lerner, supra note 17.
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B. The Non-Compete Function of Patents
There are advantages to owning a patent. Patents protect individual inventors
who have no ties with multinational drug manufacturers against “deliberate
misappropriation and good-faith origination of the same or similar inventions.”24
Thus, with a patent, a new inventor can establish credibility and gain recognition in
his respective industry to attract larger research grants for the development of new
products.25
Patents benefit the inventor and the public who will use or consume the patented
invention. Suppose Cosmore has a patent on a cholesterol-lowering drug. Doctors
find that the Cosmore drug is more effective than any other drug on the market;26
therefore, they begin prescribing the drug to more patients.27 In turn, Cosmore sells
more of the drug. Thus, sales of the drug generate more profits for further research
and development to create other drugs that can work even better for patients than the
current drug can.28
The accumulation of higher revenues for research and development is an
important advantage of patents. This exclusive patent protection means, however,
that the patent holder can charge whatever price he wants. Moreover, a growing
phenomenon is that revenue intended for research and development is actually being
spent on advertising, marketing, public relations, and administration.29 According to
Illinois Governor Rod Blagojevich, “since the [Food and Drug Administration]
relaxed advertising restrictions for U.S. drug manufacturers in 1997, spending on
advertising jumped from $719 million to $2.5 billion annually.”30 Therefore, while
patents are advantageous in some respects, these advantages have been exploited by
some businesses for pure profits and market control.31
C. Adoption of Compulsory Licensing in the United States
Compulsory licensing should be adopted in the United States because the skyrocketing costs of pharmaceutical drugs are an immediate public health care concern
for millions of senior citizens.32 The high cost of prescription drugs in the United
24

Id. at 8.

25

Id.

26

See Hart, Zaharoff & Lerner, supra note 17, at 2. This article explains that patents
reward the ingenuity and the risks that inventors undertake to create new products and
processes.
27

Id.

28

Barnes, supra note 15. “Without patent protection, pharmaceutical development would
lose its profitability and ultimately its momentum.” Id. at 911.
29

Harper, supra note 13.

30

Id.

31

Id.

32

Barry, supra note 1, at 2 (reporting that senior citizens are sometimes using dangerous
methods to cope with the high cost of pharmaceutical drugs); see also Medicare Reform, supra
note 2.
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States is adversely affecting the ability of many senior citizens to purchase necessary
medicine.33 Reports indicate that, on average, each senior citizen spends $2,300 a
year on prescription drugs.34 In a large number of cases, these senior citizens do not
have a suitable prescription drug plan that will pay for their expenses.35
Furthermore, the recent enactment of the Medicare Reform Act has prohibited online purchases from many foreign sources, including Canada, where price controls
have kept the cost of prescription drugs down to levels 50 to 75 percent lower than
their American equivalents.36 Therefore, compulsory licensing provides a swift
solution to this health care crisis because it forces pharmaceutical companies to
license important drug patents for the immediate manufacture of cheaper generic
drugs.
III. ANALYSIS OF THE 2003 MEDICARE REFORM ACT
Before the proposal for compulsory licensing with reasonable royalties is made,
this section will look more closely at the Medicare Reform Act and how the
prescription drug benefit will work.
A. Introduction
On December 8, 2003, President George W. Bush signed into law the Medicare
Reform Act.37 In theory, the Medicare Reform Act provides forty million Medicare
recipients a newly revised health care plan with a prescription drug benefit.38 In
reality, after thirty-eight years of waiting and depleting hard-earned retirement
savings on medical expenses and daily prescription drugs, seniors face a fiasco. The
prescription drug benefit that was originally priced at $400 million, prior to its
passage two months ago, has been recalculated and projected to cost at least $530
million in ten year—an increase of one-third.39 More shockingly, even with this
increased spending, Federal Medicare officials are finalizing their decision on
whether to pay for all uses of some important cancer drugs.40 Many in the medical
field fear that the decision to not cover certain drugs will set a dangerous precedent
that may have serious repercussions on the treatment of many diseases in this
country.41
33

Barry, supra note 1; see also Medicare Reform, supra note 2.

34

Harper, supra note 13.

35

Id.; see also Barry, supra note 1; Medicare Reform, supra note 2.

36

See Patricia Barry, More Americans Go North For Drugs, Apr. 2003, at
http://www.aarp.org (on file with author); see also infra Chart 2 and accompanying note 64.
37

Medicare Reform Act, supra note 13.

38

Id.

39

Robert Pear, Bush’s Aides Put Higher Price Tag on Medicare Law, N.Y. TIMES, Jan. 30,
2004, at A1, A15.
40

Gardiner Harris, U.S. Weighs Not Paying For All Uses Of Some Drugs, N.Y. TIMES, Jan.
30, 2004, at C1, C5.
41

Id.
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Many legislators from both the democratic and republican parties argue that the
prescription drug benefit was a gift to the multinational drug manufacturers and
pharmaceutical industry lobbies.42 Conversely, drug manufacturers extol the
Medicare Reform Act as “the most important, pro-patient Medicare reform in the
program’s [thirty-eight] year history.”43 To better understand the arguments for and
against the new Medicare prescription drug benefit, the following section will
analyze its various provisions and then discuss the option of importing prescription
drugs from Canada.
B. A Closer Look at the Prescription Drug Benefit
The purpose of the voluntary prescription drug benefit is to provide medicine to
Medicare recipients at reasonable prices.44 There are, however, serious concerns
about whether the drug plan is worthwhile. The following will shed light on the
provisions of the drug plan by defining who is covered, how much is covered, and
what costs are associated with each.
First, all eligible Medicare recipients and eligible Medicaid recipients will be
eligible for this drug benefit. For the first time, low-income seniors who were not
eligible for Medicaid will have an opportunity to receive the prescription drug
coverage.45 The following chart will describe how the new change in benefits will
affect low-income beneficiaries.

42
See generally Press Release, Edward M. Kennedy, Senator Edward M. Kennedy
Intr[o]duces The Health Security and Affordability Act, (Jan. 22, 2004), at
http://kennedy.senate.gov, (on file with the author) [hereinafter, Kennedy Press Release];
Donald L. Bartlett & James B. Steele, Why We Pay So Much For Drugs, TIME, Feb. 2, 2004,
at 11-12; Ceci Connolly, Drugmakers Protect Their Turf, WASH. POST, Nov. 21, 2003, at A04
(on file with author).
43
Alan F. Holmer, Statement by Alan F. Holmer, President and CEO, PhRMA, on Signing
of the Medicare Prescription Drug Benefit into Law, (Dec. 8, 2003), at http://www.phrma.org
(on file with the author).
44

Medicare Reform Act, supra note 13; Patricia Barry, The New Medicare And You,
AARP BULLETIN, Jan. 2004, at 16-18, 20. This informative article uses sources from inside
and outside the American Association of Retired Persons to explain the impact the Medicare
Reform Act will have on Medicare recipients. The author indicates that although the drug
benefit is voluntary, the government encourages early enrollment to avoid higher premium
penalties. Id. “The [government’s] rationale is to ensure that healthy as well as sick
beneficiaries take part, spreading the insurance risk so costs are held down and the program
remains viable.” Id. at 16.
45

Elizabeth Auster, Prescription Drug Plan Nears Senate Approval, PLAIN DEALER
(Cleveland), Nov. 25, 2003, at A1, A10. Republicans have argued that the new drug benefit
provides low-income seniors “who are not poor enough to be eligible for Medicaid,” to have
access to drug coverage for the first time. Contra Susan Jaffe, Plan To Cost Ohio’s Poorest
Seniors More For Drugs, PLAIN DEALER (Cleveland), Nov. 25, 2003, at A10. According to
Ohio Republican Sen. Mike DeWine and health care advocates, the Medicare drug benefit will
provide less coverage for low-income seniors than their Medicaid counterparts. Edwin Park,
senior health policy analyst at the Center on Budget and Policy Priorities in Washington, D.C.
said, “People could be paying more and getting fewer drugs covered.” Id. “For the poorest of
the poor, this is not a benefit . . . . What they have now is much better than what they will get,”
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CHART 1: Outline of Coverage for Qualified Low-Income Beneficiaries46

Income Level and
assets (subject to
inflation) for
individuals (i) and
couples (c)
Under $9,630 (i)
and under
$13,000 (c)
Up to $13,000 (i)
(with assets below
$6,000) and up to
$17,550 (c) (with
assets below
$9,000)
Up to $13,000 (i)
(with assets from
$10,000) and up to
$17,550 (c) (assets
from $20,000)
Up to $14,450 (i)
(with assets from
$10,000) and up to
$19,500 (c) (with
assets from
$20,000)

In 2006, enrollee
will receive
health coverage
from

Premiums and
deductibles (to
start in 2006)

Drug co-payments
for generic drugs
(g) and brand-name
drugs (b) for a
thirty-day
prescription

Medicare and
Medicaid

No premiums and
no deductibles

$1(g) and $3(b)

Medicare

No premiums and
no deductibles

$2(g) and $5(b)

Medicare

No premiums but
$50 deductible

15 percent(g) &
15 percent(b)

Medicare

Sliding scale

Sliding Scale

While coverage for low-income individuals appears to be quite expansive, the
new prescription drug plan will not cover all the out-of-pocket expenses for
prescription drugs, which was common under Medicaid.47 Therefore, the new
prescription drug benefit will require everyone to pay out-of-pocket costs—even the
poorest of the poor.48

said Gail Long, director of Merrick House, “which serves 4000 seniors and other residents of
Cleveland’s near West Side.” Id.
46
Barry, supra note 44, at 17. Fortunately, qualified low-income citizens will not have to
suffer from the consequences of the gap in coverage that many middle- and higher-income
seniors will have to undergo.
47

Jaffe, supra note 45, at A10.

48

Auster, supra note 45; Jaffe, supra note 45.
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Second, the plan establishes co-payments and premiums for prescription drug
coverage on a graduated scale for middle-income and higher-income citizens.49 In
general, beginning in January 2006,50 after each beneficiary has paid a $250
deductible, he will be required to pay 25 percent for all prescription drugs up to
$2,250.51 Then, once the beneficiary has personally spent $3,600 in prescription
drug costs, plus $1,500 in premiums, the drug benefit will cover as much as 95
percent of all remaining costs.52
As the figures indicate, for all drug costs between $2,250 and $3,600, there will
be no drug coverage available for most beneficiaries. This “doughnut hole” in
coverage is another point of contention for opponents of the Medicare Reform Act.53
For an average fixed-income couple that spends $2,300 each on prescription drugs,
adding up to $4,600, this “doughnut hole” is increasingly burdensome because the
plan requires that each beneficiary spend $3,600 before he or she can receive the
subsequent benefit.54 To worsen matters, Medicare has forbidden the purchase of a
supplemental drug benefit that will “fill in” the gap.55 For this reason, many states
are looking into importing prescription drugs from Canada where prices are
considerably cheaper due to government-imposed price controls. (See infra Section
IV.C.)
While the drug benefit attempts to provide better prescription drug coverage, the
costs of the plan have raised great concern for bipartisan legislators and health care
advocates.56
C. Canadian Importation of Legal Prescription Drugs
Following the lead of many American seniors, many state and local governments
have either implemented or are devising prescription drug plans in association with
Canadian pharmacies to provide cheaper prescription drugs for their state citizens.
For example, Springfield, Massachusetts has already begun importing prescription
49

Barry, supra note 44.

50

Id. at 18. Until the plan becomes effective, in June 2004 through 2005, the federal
government is providing any interested recipients a discount card that will help alleviate some
of the cost of prescription drugs. The discount card will give a $600-a-year credit for qualified
low-income beneficiaries. Id.
51

Id.

52

Id.

53

Id.

54

Id. See also Medicare Overhaul: How It May Affect You, PLAIN DEALER (Cleveland),
Nov. 25, 2003, at A1, A10. This article answers similar questions that senior citizens may
have about the Medicare Reform Act and provides information from CCH Inc., Scripps
Howard News Service, and Cox News Service.
55

Barry, supra note 44, at 18. In spite of the large gap in coverage, “the new law will not
allow [the beneficiary] to have both the Medicare drug benefit and a medigap policy that
includes drug benefits.” The author notes, however, that “retiree benefits from former
employers could be used to fill in these gaps.” Id.
56

Id.; Auster, supra note 45; Jaffe, supra note 45.
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drugs from CanaRx Services, a Canadian on-line pharmacy located in Windsor,
Ontario, for 1,600 of its insured city employees, retirees, and their dependents.57 In
one year alone, savings have been estimated at $4 to $9 million.58 Despite the
advantages of importation to so many seniors and fixed-income citizens, the U.S.
Food and Drug Administration, (“FDA”), has moved to enjoin Canadian on-line
pharmacies from supplying prescription drugs to Americans. The FDA’s rationale is
that Canadian imports pose health risks to the consumer because improper shipping
and handling pose the risk of contamination.59 This section will analyze the FDA’s
response to importation in view of the recent Oklahoma district court decision in
United States v. Rx Depot.60
1. State and Local Governments Propose Canadian Drug Importation Plan
Illinois, Michigan, Massachusetts, Vermont, Wisconsin, Iowa, California, New
York, Kentucky, and Minnesota are all following Springfield, Massachusetts’s lead
and are seriously looking into the importation of prescription drugs from Canada to
battle the high cost of drugs being sold by the U.S. manufacturers.61 All these states
are chanting the need for cheaper prescription drugs for their citizens. With the
recent passage of the Medicare Reform Act, which prohibits the federal government
from negotiating drug prices, all these states see Canada as the immediate solution.62
In fact, in 2002 alone, Canadian drug imports “topped $700 million (U.S.) . . . a
[fifty-fold] increase over three years.”63 The following chart shows the price
differential of a typical prescription in the United States and in Canada.

57
Elizabeth Mehren, City Finds A Cure For Drug Costs in Canada, L.A. TIMES, Nov. 1,
2003; Harper, supra note 13. “The average savings for the city [of Springfield] on each
prescription is 40 per cent, but can range as high as 80 per cent . . . with its ‘Buy Canada
Plan.’” Id.
58
Id; Egan, supra note 5, at 2; see also Christopher Rowland, Democrats Embracing Drug
Imports Presidential Hopefuls Hit Firms Amid Rising Interest in the Issue, B. GLOBE, Nov. 6,
2003, at C1 (focusing on the favorable positions of the various Democratic Presidential
candidates regarding prescription drug imports from Canada).
59

Press Release, FDA Strengthens Controls, Issues Consumer Alert On Importing Certain
Prescription Drugs, FDA NEWS, Dec. 9, 2002, available at http://www.fda.gov/
bbs/topics/news/2002/NEW00856.html [hereinafter FDA Press Release]; Egan, supra note 5;
Harper, supra note 13.
60

290 F. Supp. 2d. 1238 (N.D. Okla. 2003).

61

Harper, supra note 13; Egan, supra note 5; Mehren, supra note 57.

62

Medicare Reform Act, supra note 13, at subpart 2(i) provides as follows:
(i) Noninterference.—In order to promote competition under this part and in carrying
out this part, the Secretary—(1) may not interfere with the negotiations between drug
manufacturers and pharmacies and [Prescription Drug Plan] sponsors; and (2) may not
require a particular formulary or institute a price structure for the reimbursement of
covered part D drugs.
Medicare Reform Act, supra note 13.
63

Harper, supra note 13.
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CHART 2: Price Differential of Top-Selling Brand-Name Prescription Drugs in the
United States and Canada64
Brand-Name Drug
Lipitor (Pfizer)
Zocor (Merck)
Prilosec (AstraZeneca)
Procrit (Johnson &
Johnson)
Norvasc (Pfizer)
Zyprexa (Eli Lilly)
Paxil (GlaxoSmithKline)
Prevacid (TAP
Pharmaceutical)
Celebrex (Pfizer)
Zoloft (Pfizer)

United States (US $)
$272 to $308
$372 to $451
$108 to $126

Canada (US $)
$159 to $199
$198 to $244
$62 to $81

$282

N/A

$128 to $150
$526 to $616
$243 to $309

$113 to $136
$358 to $433
$152 to $189

$382 to $450

$181 to $210

$145 to $177
$222 to $248

$63 to $71
$140 to $172

Therefore, state and local governments want to establish plans that would permit
the legal importation of Canadian drugs to provide their citizens with cheaper
prescription drugs. This in turn will create considerable savings to state government
health care budgets because they will be able to recoup some of the costs associated
with subsidized prescription drug plans.65
2. The Food and Drug Administration’s Response to Importation:
United States v. Rx Depot
Responding to concerns about the safety of Canadian legal prescription drug
imports, in late October, Illinois Governor Rod Blagojevich announced recent
research findings that showed “that Canadian pharmacies were as safe as those in the
U.S.” and in some cases more safe.66 The FDA and the multinational drug
companies disagree and warn that unmonitored importation of foreign-manufactured
drugs pose health risks. Thus, the FDA and the drug companies are targeting the
American retail pharmacies that have entered into joint ventures with Canadian
pharmacies to sell Canadian drugs in retail stores in the United States or through the
Internet. GlaxoSmithKline has threatened to cut supplies to Canadian sellers that
reimport American-manufactured drugs.67 Eli Lilly has threatened criminal
64

Bartlett & Steele, supra note 42, at 11-12 (investigating the reasons why prescription
drugs cost more in the United States, dissecting the arguments made for and against
importation, and providing financial statistical comparisons among the U.S. and several other
countries).
65

For more information regarding Michigan Governor Jennifer M. Granholm’s state health
care plan, see generally http://www.michigan.gov (last visited Aug. 18, 2004).
66

Mehren, supra note 57.

67

Jackie Judd, Closing Options: Drug Companies, FDA Move To Block Import Of LowCost Canadian Prescriptions, ABC NEWS, Mar. 13, 2003, available at http://www.abc
new.go.com (on file with author).
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prosecution of Canadian wholesalers that defy the Food, Drug, & Cosmetic Act.68
The FDA has already begun prosecuting retail stores that import or reimport
prescription drugs from Canada.69 United States v. Rx Depot illustrates the
troublesome logic of the FDA’s arguments against the importation of foreign-made
drugs.70
Rx Depot, Inc. and Rx of Canada (collectively, “Rx Depot”) are retail
pharmaceutical suppliers, incorporated under the laws of Nevada, that operate
eighty-five stores throughout Canada and the United States and serve 800 customers
a day through their on-line service and/or through brick and mortar sales.71 Its sales
procedure is as follows: Once an Rx Depot customer has submitted his doctor’s
prescription and the requisite credit check and health information forms, a Canadian
doctor then rewrites the prescription and submits that prescription to a Canadian
pharmacy that fills the order according to that prescription.72
In Rx Depot, the FDA sued Rx Depot in Oklahoma federal district court to enjoin
it from continuing to import and sell pharmaceutical drugs from Canada.73 The
district court held that Rx Depot was guilty of violating a federal law intended to
protect the public health and safety. Thus, the court ordered a preliminary injunction
against Rx Depot that would prohibit it from continuing to import and sell
prescription drugs from Canada.74
Interestingly, while the overriding issue of the case was a per se violation of a
federal statute, the court dedicated a large portion of its opinion to the purported
dangers of importing drugs from Canada. Even though these arguments are made in
dicta, they are, nevertheless, significant because they provide a faulty legal
foundation for arguments against importation. The court’s rationale is based on four
questionable allegations made by the FDA.75
First, the FDA alleged, and the court agreed, that the manufacturing and storage
safety guidelines used to produce Canadian imports are less predictable. Therefore,
according to the FDA, Canadian imports may cause more adverse side effects on
American consumers than the FDA-sanctioned guidelines for drugs manufactured
and obtained in the U.S.; that is, because the imported drugs are not continuously
monitored by the FDA.76 Conversely, at a June 2003 bipartisan congressional
68

Id.; see Food, Drug, and Cosmetic Act, 21 U.S.C § 331 (2003).

69

Rx Depot, 290 F. Supp. 2d. at 1240.

70

Id. at 1238.

71

Id. at 1240.

72

Id. at 1241.

73

Id. at 1239.

74

Rx Depot, 290 F. Supp. 2d. at 1247-50.

75

Id. at 1241-43.

76

Id. at 1241-42. Specifically, the court finds that “the drugs may be contaminated,
counterfeit, or contain erratic amounts of the active ingredient or different excipients. Also,
the drugs may have been held under uncertain storage conditions, and therefore be outdated
or subpotent.” Id. (emphasis added).
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hearing on the issue of the safety of legal prescription drugs imported from Canada,
Associate FDA Commissioner William Hubbard denied that Americans have been
hurt from adverse effects of Canadian drug imports.77 When Senators Dan Burton,
(D-Indiana), and Gil Gutknecht, (R-Minnesota), asked Mr. Hubbard to present
corroborative examples that showed that American consumers had been injured from
imported Canadian legal prescription drugs, Mr. Hubbard answered that he had no
such evidence.78 Therefore, the FDA lacked concrete evidence that inferior
Canadian manufacturing and storage safety standards pose a threat to public health.
Second, the court insisted that Rx Depot’s frequent mistakes, in supplying more
pills than prescribed, may cause unintentional overdose because the American
patient could “take a drug for many days more than their physicians intend without
supervision.”79 While this allegation is troubling, it is also based on an unproven
presumption. The court presumes that the threat of overdose is prevalent in the
United States only because foreign pharmacies are giving patients more pills than are
prescribed by the patient’s doctor. Actually, the American Association of Retired
Persons (“AARP”) reported that some senior citizens are trying to save money on
prescription drugs purchased in the United States by consuming pills of a higher
strength—taking forty (40) mg as opposed to the prescribed twenty (20) mg because
they cost the same—and then skipping doses to accommodate for the higher
strength.80 Therefore, the allegation that purchasing medication from foreign
sources, rather than domestic sources, can lead to danger is seriously misleading to
the American public.
Third, the court found that, although no one has been harmed by any legal drugs
imported by Rx Depot, this fact “does not diminish the legitimate safety concerns of
the FDA.”81 As Mr. Hubbard explained above, there is no evidence that legal drugs
imported via Rx Depot or any other Canadian source have injured anyone. By
comparison, American statistics show that “[each] year an estimated 50,000 to
100,000 people die as a result of adverse reactions from FDA-sanctioned
pharmaceutical drugs sold in the [United States].”82 Therefore, this allegation of
potential future harm to American customers of Rx Depot is also unjustified.
Fourth, the court found that an undercover investigation of Rx Depot’s quality
control revealed that the packaging of “foreign-manufactured version of Serzone,
known as APO-Nefazodone,” a particularly dangerous anti-depression drug, did not

77

Bartlett & Steele, supra note 42, at 6-7.

78

Id.

79

Rx Depot, 290 F. Supp. 2d. at 1242.

80

Barry, supra note 1. For more on splitting pills, please refer to http://www.aarp.org/
bulletin/prescription/Articles/g2003-09-30-splittingpills.html, which provides a guide on the
“Do’s and Don’ts of Splitting Pills”.
81

Rx Depot, 290 F. Supp. 2d. at 1242.

82

Bartlett & Steele, supra note 42, at 6; see FDA Press Release, supra note 59: “According
to a 1999 report by the Institute of Medicine, medical errors in hospitals alone cause annually
40,000 to 98,000 deaths. The IOM has estimated that preventable adverse events cost the
United States economy $17 billion a year.” Id.
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contain the requisite warning inserts that intake could cause liver failure.83 Unlike
the third allegation discussed above, substantial evidence of the dangers of the drug
supports this allegation; therefore, Rx Depot’s failure to warn the consumer against
adverse effects of the drug is a per se statutory violation. The court used this
omission to show that the FDA’s health and safety standards are superior to those of
many foreign countries, including Canada.84 In the case of Serazone, the FDA’s
superior standards are somewhat questionable. While the FDA has only required
that a stamp be placed on the drug’s packaging, which warns the American patient of
the drugs dangerous side effects, Canada has banned the use and sale of the drug
completely.85 Canada banned the domestic sale of Serazone after the drug patent
holder Bristol-Meyers announced that it would withdraw the drug from Europe and
Canada.86 Therefore, although Rx Depot’s failure to warn patients of the dangers of
Serazone was an illegal act, the court’s reliance on the superiority of the FDA’s
standards as a reason to ban importation of drugs is faulty.
Rx Depot affirms the United States’ contrary stance on importation of legal
prescription drugs from Canada as a remedy for the high cost of prescription drugs in
the United States. For this reason, compulsory licensing provides the most
immediate relief to millions of seniors as they await a final decision on the issue of
importation.
IV. UNITED STATES’ ENDORSEMENT OF COMPULSORY LICENSING
DURING A NATIONAL CRISIS
Rx Depot affirms the United States’ current policy of banning commercial
importation of drugs from Canada as illegal and non-discretionary; thus, a federal
policy that allows commercial importation is not a viable and immediate option that
can help lower the cost of prescription drugs for millions of seniors.87 Because many

83

Rx Depot, 290 F. Supp. 2d. at 1242-44.

84
Id. at 1243. The court’s tone used to criticize the Canadian instructions is not justified:
“For example, the Canadian instructions do not specify some of the liver failure symptoms
listed on the Serzone insert, do not mention drugs that should be avoided when taking APONefazodone, and do not convey the sense of urgency reflected in the Serazone insert. These
substandard instructions could increase the risk of adverse events . . . .” Id. (emphasis added).
The court ignores the importance of communication between doctors and patients when
certain treatments have potentially dangerous side effects.
85

Bartlett & Steele, supra note 42, at 7; see FDA Press Release, supra note 59. The FDA
released this statement in December of 2002, five months prior to its undercover purchase
through Rx Depot. Serazone is not listed on the Import Alert list.
86

Bartlett & Steele, supra note 42.

87

Rx Depot, 290 F. Supp. 2d. at 1248. “FDA’s personal importation policy outlines
specific circumstances in which the agency generally will decline to prosecute the illegal
importation of small quantities of prescription drugs by individuals. By its express terms, this
policy of enforcement discretion does not apply to commercial operations such as Rx Depot.”
Id. Contra Hughes v. Alexandria Scrap Corp., 426 U.S. 794 (1976) (holding that a state
statute can discriminate against out-of-state suppliers if the state does so as a market
participant and refrains from regulating the whole market structure itself). State and local
legislation that permit the state and local government to enter into supply agreements with
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in the federal government believe that health care should be available for senior
citizens, a federally mandated plan to lower prescription drug costs must be
immediately implemented. Thus, compulsory licensing with reasonable royalties is
the measure that can meet this need.
The United States has recognized compulsory licensing with reasonable royalties
as an appropriate remedy for antitrust violations in an international and a national
context. The following section will look at the United States’ international and
national endorsement of compulsory licensing, and then respond to arguments made
against compulsory licensing in an American context.
A. International Law Recognizes Compulsory Licensing as a
Price-Lowering Measure
1. The United States is Bound to the Agreement on Trade Related Aspects
of Intellectual Property Rights
As a founding signatory of the World Trade Organization (“WTO”) and the
Agreement on Trade Related Aspects of Intellectual Property Rights (“TRIPS
Agreement”), the United States recognizes compulsory licensing with reasonable
royalties to combat high prescription drug costs in the international arena.88
Upon signing the TRIPS Agreement, the United States agreed that the federal
government may “adopt measures necessary to protect public health and nutrition,
and to promote the public interest in sectors of vital importance to their socioeconomic and technological development.”89 This provision is a recognized
endorsement of compulsory licensing of patents.90
Moreover, in November 2001, while meeting in Doha, Qatar, the WTO expressly
declared that member states could grant compulsory licenses for patented
pharmaceutical drugs to respond to a national crisis (“Doha Declaration”).91 In fact,
paragraph four of the Doha Declaration states that the TRIPS Agreement should be
interpreted to support “WTO Members’ right to protect public health, and in
particular, to promote access to medicine for all.”92 Furthermore, paragraph five,
section (b) affirms that each Member of the TRIPS Agreement “has the right to grant
retail pharmacies in Canada could be protected under the Market Participant Exception of the
Dormant Commerce Clause.
88
See INTERNATIONAL TREATIES ON INTELLECTUAL PROPERTY 585-87 (Marshall A. Leaffer,
ed., 2d ed., 1997). On April 15, 1994, in Marrakesh, 112 countries, including the United
States, Canada, and India, formed the World Trade Organization. Id. at 585. Article II of the
Marrakesh Agreement that established the World Trade Organization bound all member states
to the Agreement on Trade Related Aspects of Intellectual Property Rights.
89

Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994,
Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, LEGAL
INSTRUMENTS—RESULTS OF THE URUGUAY ROUND vol. 31, 33 I.L.M. 81, art. 8, § 1 (1994)
[hereinafter TRIPS].
90

Kriparuri, supra note 11, at 3.

91

Doha Declaration, supra note 7, at ¶ 5(b), (c).

92

Id. at ¶ 4 (emphasis added).
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compulsory licenses and the freedom to determine the grounds upon which such
licenses are granted.”93
As a member of the international community, the United States agrees that
compulsory licensing is an appropriate remedy for national crises. Since the United
States signed the TRIPS Agreement, it must implicitly recognize compulsory
licensing for its citizens as well.
2. The United States is in a National Crisis
The World Trade Organization has left defining “national crisis” to the member
state because each country has defined “crisis” according to its own circumstances.94
The current health crisis in the United States is a major concern for Americans
today.95 Legislators and public interest groups have been trying for years to respond
to the rising cost of prescription drugs and hospital care.96 Forty million Medicare
recipients in this country are looking for a solution.97 In 2002, the median income
for senior citizens in this country was $13,994.98 As mentioned above, the new
prescription drug benefit prohibits seniors from purchasing supplemental
prescription drug plans to bridge the coverage gap.99
These indicators fall within the scope of a national crisis as described by the
Doha Declaration, which the United States has internationally endorsed. As the
Doha Declaration states, nations must “promote access to medicine for all” and to do
this, they can order compulsory licensing of important patented drugs to meet the
public’s needs. In the United States, the rising cost of pharmaceutical drugs has
prevented millions of people access to necessary medication.100 Many seniors have
been taking desperate measures to cope with this problem, such as, foregoing
medical treatment, skipping doses and splitting pills.101
Therefore, under
international law, the United States has the power to implement compulsory
licensing in order to respond to the health care crisis.

93

Id. at ¶ 5(b).

94

Id. at ¶ 5(b), (c).

95

Kathleen Pender, Study: Fewer Companies Offering Pensions, S.F. CHRON., Nov. 23,
2003 (reporting that there are more retired persons than employed persons and that the
available funds in retirement pensions have been shrinking).
96

See, e.g., Kennedy Press Release, supra note 42.

97

Barry, supra note 1.

98

Income of the Elderly Population, EBRI Notes Executive Summary, Nov. 2003, at
http://www.ebri.org/notesx/1103note.htm.
99

Barry, supra note 44, at 18.

100

See, e.g., Pfizer Statement on Maine Rx Ruling, PR NEWSWIRE, May 22, 2003.

101

Barry, supra note 1.
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B. United States Case Law Supports Compulsory Licensing as an Antitrust Remedy
Often, the United States’ international position is not aligned with its national
stance on particular issues.102
Fortunately, the United States case law has
historically accepted compulsory licensing of patented products to respond to serious
antitrust violations. This section will analyze three cases that have established
compulsory licensing as an appropriate solution to unfair commercial trade practices
in the United States: (1) Hartford-Empire Co. v. United States; (2) American
Cyanamid v. United States, and (3) United States v. Glaxo Group.
1. Hartford-Empire Co. v. United States
Hartford-Empire Co. v. United States is a seminal case that dealt with patent
misuse and the imposition of compulsory licensing as a proper judicial remedy.103
The Supreme Court held that compulsory licensing with reasonable costs and
royalties can be imposed against a corporation if its “system of restricted licensing”
prohibits the “invention” of a product, prevents “the manufacture and sale or
licensing of” that product, “suppresses competition” and establishes a price-fixing
scheme.104 The Supreme Court said that compulsory licensing “covers every kind of
invention and every patent, present or future, in any field if owned or controlled or
distributed by [the violating corporation].”105 Thus, the Supreme Court recognized
that compulsory licensing with reasonable royalties is an acceptable antitrust
remedy.106
Hartford illustrates when compulsory licensing with reasonable royalties is an
appropriate-, and sometimes only, remedy to stop corporations from destroying the
free market system.107 Twelve major glass-manufacturing companies created an
oligopoly by combining their exclusive patents on important glass manufacturing
equipment designs.108
The oligopoly unfairly restricted individual glass
manufacturers from competing in the industry because it collusively held these
patents.109
Eventually, the oligopoly controlled 94 percent of the glass
manufacturing equipment industry.110
Compared to Hartford, the multinational pharmaceutical companies are pursuing
unfair trade practices because they are misusing their patent rights to restrict
competition in the American market and are prohibiting international legal

102
Examples include the International Court of Justice, the Kyoto Agreement on CO2
emissions, and the 1997 Mine Ban Treaty.
103

323 U.S. at 400-02.

104

Id. at 400, 419.

105

Id. at 422-23.

106

Id. at 419-23.

107

Id. at 392, 400.

108

Id.

109

Id.

110

Id.
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prescription drugs sales to American citizens.111 This anticompetitive behavior is
adversely affecting consumers’ ability to purchase cheaper prescription drugs.112 The
recent controversies that surrounded the eventual passage of the Medicare
Prescription Drug and Modernization Act (“Medicare Reform Act”) show that the
major lobbying tactics of the pharmaceutical industry in the United States led to
stricter efforts to prevent importation of cheaper prescription drugs from Canada and
Europe, and moreover, the inclusion of a provision in the Act itself that “explicitly
prohibits the federal government from negotiating prices on behalf of Medicare
recipients.”113
In accordance with Hartford, the courts should order the
pharmaceutical industry to license their patents to drug manufacturers to produce
generic versions of certain patented drugs, which would reduce prescription drug
prices. While limiting the exercise of patents will adversely affect shareholder
wealth maximization and the amount of future investments, consumers make up
another equally important constituency, which corporate governance requires
pharmaceutical companies to recognize, because consumers are the end-users of the
pharmaceutical companies’ product.114
2. American Cyanamid v. United States
In American Cyanamid v. United States, the Sixth Circuit Court of Appeals
considered several allegations of patent misuse and collusion against American
Cyanamid, Pfizer, and three other multinational pharmaceutical companies.115 First,
the court considered whether American Cyanamid and Pfizer had made false and
misleading statements to the U.S. Patent Office during an interference proceeding,
which is a procedure that the patent office uses to determine which inventor has
priority status over a specific invention; in this case, the invention was
tetracycline.116 Second, the court analyzed allegedly misleading testimony that
American Cyanamid and Pfizer gave to the U.S. Patent Office to make sure that
Pfizer received the patent on tetracycline.117 Third, the court considered whether
there was enough evidence to show that American Cyanamid and Pfizer had entered
into a subsequent cross-licensing agreement.118 Next, the court evaluated an alleged
price fixing scheme that American Cyanamid, Pfizer and three other multinational
111
Patricia Barry, Crackdown In Canada, AARP BULLETIN, Feb. 2004, at 18. According
to this article, Pfizer, Inc. has sent a letter to all Canadian pharmacies “threaten[ing] to cut off
all supplies of its products to any pharmacy that helps the cross-border trade.” Id.
112

Id.

113

Connolly, supra note 42; see Medicare Reform Act, supra note 13: “Subpart 2,
Prescription Drug Plans” contains three paragraphs that make it illegal for the federal
government from negotiating drug prices with drug manufacturers.
114

See generally ROBERT A.G. MONKS & NELL MINOW, CORPORATE GOVERNANCE (2d ed.

2001).
115

363 F.2d 757, 761-62 (6th Cir. 1966).

116

Id.

117

Id.

118

Id.
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pharmaceutical companies had established.119 Finally, the court determined whether
the activities of the five pharmaceutical companies had “the effect of hindering,
foreclosing, and eliminating competition in the sale of antibiotics and . . . continue to
have the dangerous tendency of creating a monopoly in Pfizer.”120
Although the court eventually vacated and remanded the case after the
Commission was dismissed from the case because of a conflict of interest, the court
relied on Hartford and other past precedent that recommended the restraint of the
impervious quality of patent protection.121 First, the court said that patent holders are
prevented from creating monopolies that would adversely affect the public interest,
which patents are designed to protect.122 Thus, comparing the facts in American
Cyanamid, currently, the pharmaceutical companies have returned to their collusive
ways to accumulate profits to meet shareholder expectation by misusing their patent
protection and charging unconscionable brand-name drug prices to millions of fixedincome Americans who are forced to pay for multiple prescriptions for various
chronic and temporary ailments.123
Second, the court said private suits can be brought against patent holders under
section four of the Clayton Act for Sherman Antitrust violations.124 In the current era
of soft-money donations and powerful special interest groups, senior citizens and
other fixed income individuals need a strong public interest group that will be able to
formidably fight for and win lower prescription drug prices for Americans.
Third, and most important, the court stated that compulsory licensing with
reasonable royalties is a permissible antitrust remedy against patent misuse,
especially when there is substantial evidence that a pharmaceutical patent holder has
placed its own interests above the needs of the public that it truly serves.125
Therefore, American Cyanamid provides a persuasive method to determine how
compulsory licensing with reasonable royalties can be imposed against the
pharmaceutical industry.

119

Id.

120

Id. at 762.

121

Id. at 770-72.

122

“[A] patent by its very nature is affect with a public interest … The far-reaching
social and economics of a patent, therefore, give the public a paramount interest in
seeing that patent monopolies spring from backgrounds free from fraud or other
inequitable conduct . . . .” Id. at 770 (quoting Precision Instrument Mfg. Co. v. Auto.
Maint. Mach. Co., 324 U.S. 806, 816 (1945)).

123

See supra Chart 2 and accompanying note 64.

124

[T]hat private suits maybe instituted under [section four] of the Clayton Act to
recover damage for Sherman Act monopolization knowingly practiced under the guise
of a patent procured by deliberate fraud …. Hence, as to this class of improper patent
monopolies, antitrust remedies should be allowed room for full play.
Id. at 770 (quoting Walker Process Equipment, Inc. v. Food Mach. & Chem. Corp., 382 U.S.
172, 179-80 (1965) (Harlan, J. concurring)).
125

Id. at 771-72 citing Hartford, 323 U.S. at 386: “Compulsory licensing [with royalties]
of patents by the courts for patent misuse is a permissible remedy in antitrust cases.”
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3. United States v. Glaxo Group
Relying on Hartford and American Cyanamid, in United States v. Glaxo Group,
the Supreme Court held that Glaxo Group (“Glaxo”) and Imperial Chemical
Industries Ltd. (“ICI”) were guilty of per se restraint of trade in griseofulvin, which
is used for fungal illnesses, because they would only sublicense patents on the
dosage form of griseofulvin to those companies that would not sell the compound in
bulk-form without Glaxo’s consent.126 Consequently, the Court ordered mandatory
sales and compulsory licensing against Glaxo and ICI.127
The Supreme Court held that if the public is in immediate need of a patented drug
for its health and welfare, compulsory licensing would make patent holders sell the
product in bulk, “create new competition among wholesalers, by enabling other
companies to convert the bulk drug into dosage and microsize forms and sell to retail
outlets, and would presumably lead to price reductions as the result of normal
competitive forces.”128
Therefore, the pharmaceutical industry should take heed: While holding a patent
is a constitutional privilege, using patents as economic leverage and self-interest will
lead to major regulatory repercussions.
C. Responding to Arguments Against Compulsory Licensing
While U.S. case law supports the application of compulsory licensing with
reasonable royalties when public interest outweighs commercial interests, its
opponents still criticize its application.129 This criticism has been concocted to scare
the public, rather than help prevent and/or resolve the commercial abuse for which
compulsory licensing was ordered in the first place. The following section responds
to these arguments by showing the fallacies in each.
1. Compulsory Licensing is Extortion
A commentator has equated compulsory licensing of pharmaceutical companies
with a thief coming into the home of an unassuming homeowner and forcing him to
either sell his possessions at whatever price the thief wants to pay, or else stand by
and watch as the thief takes the items and sells them at a profit.130 This description
misleads the public, and obscures the main rationale for compulsory licensing in the
United States. As U.S. case law has shown, the United States Supreme Court has
declared that compulsory licensing is a recognized federal regulatory method to
“vindicate the public interest”131 from patent misuse132 by a patent holder. Thus, the
United States uses compulsory licensing as a remedy for anti-competitive behavior.

126

410 U.S. 52, 59-62 (1973).

127

Id. at 60.

128

Id. at 63.

129

See, e.g., Hartford, 323 U.S. 386; Am. Cyanamid, 363 F.2d 757; Glaxo, 410 U.S. 52.
But see Matthews, supra note 15.
130

Matthews, supra note 15.

131

United States v. United States Gypsum Co., 333 U.S. 364, 388 (1948).
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Compulsory licensing can provide a resolution to the current prescription-drug
price war that has pitted proponents of pharmaceutical companies against numerous
consumer advocates. The American drug manufacturers assert that Canadian and
European governments have imposed price controls on prescription drugs that
artificially keep prices down.133 These price controls force American drug
manufacturers to compensate for the loss of profits from international sales needed
for new research and development by increasing the American prescription drug
prices.134 The pharmaceutical industry’s objective is the same as the objective of any
other product manufacturer: to sell its product with the hopes of maximizing profit
and meeting shareholders’ expectations.
While this aim may seem overly simplistic and selfish, the macroeconomic
principle of supply and demand governs the way the market works.135 According to
the pharmaceutical industry, American drug prices are set at levels the market is
willing to bear.136
Proponents of lower drug prices argue that the pharmaceutical companies have
been unfairly taking advantage of the market pricing structure.137 In recent months,
the pharmaceutical industry has blocked legislation that would provide cheaper
prescription drugs to senior citizens in this country.138 For instance, the debates on
the Medicare Reform Act reveal that the pharmaceutical industry forced the House
of Representatives to drop a provision that would “allow Americans to legally import
drugs from Canada and Europe, where medications retail for as much as 75 percent
less than in the United States.”139
Rather than vilifying one side and praising the other, compulsory licensing
provides a balanced solution to this problem. Compulsory licensing with reasonable
royalties offers smaller pharmaceutical companies the ability to compete in the
market by allowing them to produce and sell cheaper generic versions of brand name
drugs and provides the patent holder/licensor a share in the profits. Therefore, the
132
Glaxo, 410 U.S. at 71 n.5 (Rehnquist, J., dissenting); see also Int’l Salt Co. v. United
States, 332 U.S. 392, 398-402 (1947); Hartford, 323 U.S. 386.
133

Christopher Bowe, US Attack on European Drug Price Controls, FINANCIAL TIMES
(London), Sept. 26, 2003, at 11 (offering a European perspective on the high American drug
prices and responds to American criticism of the failure of European countries to spend more
money on research and development).
134

Id.

135

Jerry Heaster, Canadians Paying For Our Eagerness to Buy Their Drugs, PLAIN
DEALER (Cleveland), Nov. 23, 2003, at G3.
136

Id.

137

[The] clearest indication that the [Medicare Reform Act] offers a brighter future for
the [pharmaceutical] industry came from Wall Street, where pharmaceutical stock
prices [rose] . . . as the legislation’s prospects for passage improved. Analysts at
Goldman Sachs & Co. project the new Medicare benefit could increase industry
revenue by 9 percent, or $13 billion a year.
Connolly, supra note 42.
138

Id.

139

Id.
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extortion myth is false because compulsory licensing is a recognized remedy for
anti-competitive practices that adversely affect public interest.
2. Compulsory Licensing Compromises American Patent Laws and
Stifles Business Judgment
American pharmaceutical companies believe compulsory licensing infringes on
their exclusive rights under U.S. and international patent laws.140 The fears
associated with compulsory licensing are understandable. American pharmaceutical
companies can, however, and have already begun to, face the situation by joining
forces with their counterparts in the developing world to protect their interests. In
fact, in October 2003, GlaxoSmithKline (“Glaxo”) entered into a joint venture with
Ranbaxy, India’s largest pharmaceutical company.141
The language of this joint venture stated: “Under the new alliance, Ranbaxy will
identify promising potential drugs and perform early clinical trials in India, while
[Glaxo] takes care of the later-stage development. For Glaxo, one benefit would be
to accelerate the development of new products at lower cost.”142 Although Glaxo
will have exclusive commercial rights outside of India, there is the potential for
Ranbaxy “to take part in joint promotion in the U.S. and Europe.”143 Joint ventures
and outsourcing with foreign pharmaceutical companies will help American
pharmaceutical companies to efficiently use their financial resources for research and
development, which will decrease the cost of the final end-product.144 Therefore,
compulsory licensing cannot be considered as detrimental to international patent
laws as initially feared.
V. COMPULSORY LICENSING WITH REASONABLE ROYALTIES IN ACTION
For compulsory licensing with reasonable royalties to work properly in the
United States, this section makes two proposals. First, this section recommends the
formation of a tripartite healthcare commission. Second, this section proposes an
implementation strategy that encourages multinational drug companies to solidify
their relationship with Indian drug manufacturers to help keep manufacturing costs
down and profit levels up. The execution of these two recommendations will
provide the United States with greater access to cheaper prescription drugs.

140

See generally http://www.phrma.org.

141

UK drugs giant in India tie-up, BBC NEWS, Oct. 23, 2003, available at
http://www.bbc.co.uk/2/hi/business/3207169.stm, (discussing the joint venture of a
multinational pharmaceutical company and an Indian pharmaceutical company) [hereinafter,
UK-India tie-up].
142

Id.

143

Id.

144

Id.
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A. The Creation of a Tripartite Health Care Commission
1. The Organizational Structure
A tripartite health care commission (“Commission”) should be formed to ensure
that compulsory licensing with reasonable royalties is properly administered. The
Commission will be composed of three main branches: (1) a Bipartisan
Congressional Health Care Committee, (2) PhRMa, the pharmaceutical lobby, and
(3) the American Association of Retired Persons, (“AARP), the senior citizens’
lobby. Each branch will have its own function.145 First, the Bipartisan
Congressional Health Care Committee will propose legislation regarding compulsory
licensing and foreign drug importation safety. Second, PhRMa, the pharmaceutical
industry lobby, will act in its representative capacity to make sure that the reasonable
needs of the pharmaceutical industry are met: balancing lower drug costs with the
maintenance of optimal shareholder wealth maximization. Third, AARP, the senior
citizens’ lobby, will act in its representative capacity to make sure that drug prices
are affordable and accessible to all fixed income citizens. Each party will have 33
1/3 percent of the total voting rights in the Commission.
An ombudsman will act as a mediator among the legislators’ interests, the
pharmaceutical industry’s interests, and the senior citizens’ interests to make sure
that two of the parties do not place undue pressure on the third party to vote a certain
way. Only in the event of a stalemate, will the ombudsman be given the right to cast
the deciding vote on any bills that will be sent to Congress.
The Commission will be overseen by the Federal Trade Commission (“FTC”),
which will monitor antitrust issues, and the FDA, which will monitor drug safety
issues. All conflicts that cannot be resolved by the Commission and the ombudsman
will be decided in the federal court system as a final resort mechanism.
Therefore, this organizational structure of the proposed Commission will provide
an “equal access” forum for citizens and the pharmaceutical industry to meet,
discuss, propose, and, then, implement market strategies that can provide affordable
health care for citizens and guarantee adequate profit margins that generate research
and development funds for innovative medicine. (The following chart presents how
the Commission will be organized.)

145
The inspiration for this Commission comes from the U.S. Environmental Protection
Agency’s (“EPA”) state implementation plans for solid waste management. The joint federalstate plan allows states to retain their autonomy while the U.S. EPA makes sure that the states
are complying with federal environmental standards. See generally OLGA L. MOYA &
ANDREW L. FONO, FEDERAL ENVIRONMENTAL LAW (2d ed. 2001).
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CHART 3: Organizational Chart for the Tripartite Health Care Commission

2. Implementing Compulsory Licensing in the United States
To execute compulsory licensing with reasonable royalties properly, the
Commission should establish a three-year plan with essential benchmarks. The
benchmarks are dates when the cheaper generic drugs will be introduced into the
American market. Because the newly enacted prescription drug benefit of the
Medicare Reform Act will not become effective until 2006, the first benchmark
should be met immediately. The newly-formed Commission should come together
and determine which prescription drugs are most widely imported. Then, the
multinational pharmaceutical companies (“licensor”) must license the drug patents to
FDA-approved drug manufacturers (“licensee”). While strict compliance to this
strategy is essential to the effectiveness of compulsory licensing, the licensor should
be given the flexibility to negotiate with the licensee an appropriate royalty for using
the patent. Once a deal has been reached between the licensor and the licensee, the
Commission will have the final approval of the licensing contract between the two
parties to ensure that the goals of compulsory licensing as described in section IV are
achieved.
The purpose of this measure is to provide low-cost prescription drugs for all
current and future Medicare prescription-drug plan beneficiaries. For this reason, the
amount of drugs produced under the compulsory licensing measure will be limited to
a supply that meets the needs of Medicare beneficiaries. Therefore, senior citizens
and other qualified fixed-income citizens will be the ones who benefit from this
policy.
Compulsory licensing will not adversely affect the drug industry as much as has
been reported. Recent press releases from the pharmaceutical industry reveal that the
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drug industry is aware of the high cost of prescription drugs in this country.146 In
fact, even on the day that President Bush signed the Medicare Reform Act into law,
many of the major drug manufacturers were offering need-based free and low-cost
prescription drugs through their lobby website.147 This pharmaceutical industry’s
public service effort proves that drug manufacturers are able to supply cheaper or
free prescription drugs to the American consumer in spite of some loss of profits.
Therefore, the pharmaceutical industry will be able to accommodate for the loss in
profits caused by compulsory licensing.
B. Beneficial Alliance with the Indian Pharmaceutical Industry
To ensure continued good faith compliance with the implementation strategy
discussed in subsection A, the major drug manufacturers should decide which drug
manufacturers they will grant the licenses to produce the cheaper generic drugs. The
most beneficial business alliances are those that keep production costs down and
sales profits up.148 The Indian pharmaceutical industry provides the multinational
drug manufacturers this benefit. The following section will respond to concerns
regarding product safety and the expenditures related to constructing and
maintaining manufacturing facilities in India, that is, if Indian pharmaceutical drug
manufacturers are given licenses to produce generic drugs for the American market.
1. Continuous FDA-Supervision Can Allay Product Safety Concerns
The FDA and drug manufacturers claim that legal drugs made in India for
American consumption pose the risk of adverse side effects because the drugs are
produced according to lower safety control standards. The FDA and the drug
manufacturers can be assured strict quality control standards for two reasons. First,
India’s top two pharmaceutical companies, Ranbaxy, Ltd. and Dr. Reddy’s, already
supply Indian-made generic versions of drugs to the American market in compliance
146

See http://www.pfizer.com (last visited Aug. 18, 2004). Pfizer gives away free or
cheaper drugs at a 37% discount to families with incomes less than $31,000.
147
See generally http://www.phrma.org (last visited Aug. 18, 2004). This site contains
press releases from the pharmaceutical lobby regarding the Medicare Reform Act.
148

Pharmacia captures stake in Abbott India, CHEM. MKT REPORTER, Feb. 4, 2002, at 3.
Pharmacia, a multinational pharmaceutical company, increased its presence in the Indian
pharmaceutical industry with its acquisition “of a 51.5 percent stake in Abbott Laboratories
India Ltd. Abbott will maintain a strong position in the region through its majority ownership
of Knoll Pharmaceuticals India Ltd.” Id. This article also reaffirms the benefits of doing
business with Indian pharmaceutical companies.
A Pharmacia spokesperson calls the acquisition “a long-term proposition” in an
evolving market. “We are essentially trying to increase our business capabilities in a
country that has a lot of potential in the region. India will have enforceable patent and
intellectual property protection coming, WTO status and a middle class population
with an income level that gives it access to the latest Western medicine,” he adds.
Pharmacia gains the Ankleshwar, India-based manufacturing facility as well as
licenses for some products sold by Abbott in India. Abbott will retain the rights to
certain products, though details have not been announced. Abbott India Ltd. had sales
of Rp.964 million for the fiscal year ending in March 2001.
Id.
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with the strict standards of the FDA.149 (Ranbaxy sells its generic version of Ceftin,
an antibiotic drug. Dr. Reddy’s sells its generic version of Eli Lilly’s antidepressant
Prozac.150) Therefore, Ranbaxy and Dr. Reddy’s are proof that FDA-approved safety
standards are already in place in India for those generic drugs that are imported into
the United States.151
Second, the FDA can ensure that Indian drug imports comply with its safety
guidelines by requiring the presence of an FDA-approved on-site inspector at all
licensed Indian manufacturing facilities. The USDA regulates the import of foreign
cattle and poultry for the American public with the constant monitoring of an on-site
USDA inspector.152 Similarly, the FDA can have an on-site FDA inspector at the
various Indian manufacturing facilities that will monitor the production of those
drugs that will be exported to the American market. This proposal is actually
offering a stricter standard for imports than the current standard applied to foreignmanufactured brand-name drugs that are imported into this country by the large drug
manufacturers themselves.153 A recent investigation indicates that Americans are
actually buying more and more prescription drugs that were manufactured under
“minimal FDA oversight” at foreign facilities that are owned and operated by the big
drug manufacturers.154
Therefore, if multinational drug companies grant licenses to Indian drug
manufacturers who guarantee the continued presence of FDA inspectors during the
manufacture of all drugs exported to the United States, imported drug safety
concerns can be allayed.
2. Indian Drug Manufacturers and Self-Sufficiency Through Higher Profits
a. Responding to General Criticism Against Outsourcing
In the 2004 presidential campaign, the candidates and their supporters made
outsourcing (or offshoring) a hot-button issue.155 From the Democrats’ perspective,
outsourcing has hurt the U.S. job market with the transfer of many service-oriented

149

Indian Pharmaceuticals, supra note 7, at 56.

150

Id.

151

Id.; see also Anu Saraf, A Dose In Time, BUS. INDIA, Dec. 22, 2003-Jan. 4, 2004, at 3435 (on file with author) (discussing how India has become more serious about “tackling the
problem of spurious, illegal and sub-standard drugs” and has upgraded its Central Drugs
Standard Control Organization to the Central Drug Administration. The Central Drug
Administration will be implemented in three phases; the first phase is expected to begin in late
2004.).
152

See generally http://www.fas.usda.gov/itp/ofsts/us.html (providing general information
on the USDA’s importation standards).
153

Bartlett and Steele, supra note 42, at 7.

154

Id.

155

Ken Belson, Outsourcing, Turned Inside Out, N.Y. TIMES, Apr. 11, 2004.
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and manufacturing jobs to low-wage countries, such as India and China.156
Furthermore, Democrats have shone a garish light on many U.S. corporations that
have received tax breaks for outsourcing many U.S.-based jobs.157 Republicans,
industry insiders, and many economists view outsourcing as a necessary outgrowth
of free trade that “drives investment in the U.S. economy and raises our standard of
living by increasing consumer choice and creating better jobs.”158 This section will
first respond to some of the criticism made against outsourcing, and then explain
how outsourcing the production of generic drugs to India will best implement the
compulsory licensing strategy proposed.
Opponents of free trade attack U.S. companies that outsource jobs to lower-wage
countries by highlighting many current realities that result from the forced
displacement of U.S. workers. First, and foremost, critics of outsourcing highlight
the displacement of well-educated and productive American workers for lower-paid
Indian workers. While they agree that short term job loss is a “painful reality,”159
economists and other proponents of free trade counter that many of the jobs being
outsourced are low-skilled jobs “that lack prestige and suffer from high turnover
rates,” such as call-center agents, in the United States.160
Economists alleviate some of the controversies associated with this argument by
relying on the theories of absolute and comparative advantage to explain that the
outsourcing of jobs using older technology helps generate resources that can be
reinvested to create newer and more higher-valued jobs in effected industries. In its
testimony to Congress in early part of 2004, the Council of Economic Advisors
relied on Adam Smith’s theory of absolute advantage and said, “When a good or
service is produced at a lower cost in another country, it makes sense to import it
rather than produce it domestically. This allows the United States to devote its
resources to more productive purposes.” For instance, in the 1980s, Japan took away
the United States’ dominance of many segments of the semiconductor industry.161

156
Jonathan Weisman, Democrats Seize On Offshoring As Campaign Issue; Focus On Jobs
Lost During Recovery, WASH. POST, Mar. 6, 2004, at E01; Jim Miller, Outsourcing is Front
Page News in 2003: Outsourcing is in the Public Eye as Politicians Debate the Lag in Job
Growth Despite a Recovering Economy, and the Bush Administration Seeks to “Competitively
Source” More Agency Activities; Outsourcing Outlook, BIOPHARM INT’L, Oct. 1, 2003, at 20.
157

Belson, supra note 155; see also Weisman, supra note 156. Sung Won Sohn, chief
economist at Wells Fargo & Co., declared, “[O]utsourcing of jobs overseas may be playing a
part in the job market’s stagnation, helping companies increase profitability and productivity
while keeping hiring and wages depressed. With an economic recovery nearly three years old,
the economy should be producing 200,000 to 300,000 jobs a month.” Id.
158

Don Hicks, Commentary, Dispelling The Myths of Outsourcing, ROCKY MTN. NEWS
(Denver), Jul. 30, 2004.
159

Martin N. Bailey & Diana Farrell, Exploding The Myths of Offshoring, MCKINSEY Q.,
at http://www.mckinseyquarterly.com (July, 2004) (on file with author).
160
Id. Critics will dispute that prestige is not as high a motivator in parts of the United
States, where many workers must work two to three jobs a week to earn enough money for
rising health care costs and other necessaries.
161

Id.
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Consequently, Texas Instruments, Intel, and Motorola shifted their focus to newer
technologies, such as cellular phone technology. Therefore, outsourcing of certain
jobs generates higher-valued jobs.162
To counter the argument that many of the displaced U.S. workers could do better
jobs than their Indian counterparts, economists rely on David Ricardo’s comparative
advantage theory. Although more difficult to grasp, in essence, the theory explains
that the United States should outsource low-value businesses, such as insurance
processing and telephone-call centers, and “concentrate on building up business like
publishing and entertainment, where the displaced workers can be employed more
productively.”163 In fact, research over the past twenty years indicates where the
United States has seen a significant decline in manufacturing jobs, net employment
in areas such as educational and health services, professional and business services,
trade and transport, government, leisure and hospitality, and financial services have
created approximately 43 million new jobs.164 Therefore, although short-term job
losses result from outsourcing, U.S. companies are using their ingenuity to create
newer jobs by repatriating some of profits that they earn from outsourcing.
Another argument that opponents of free trade raise is that outsourcing is a oneway street that causes an “agonizingly slow pace of job growth in the United
States.”165 Proponents of free trade paint a very different picture.
Foreign direct investment, once an object of scorn, fear and
recrimination in the United States, is increasingly regarded as a source of
new jobs, production and exports….
Throughout the United States, from high-tech corridor of central Texas
to the automobile plats of the Deep South to the pharmaceutical
laboratories scattered throughout New Jersey and Massachusetts, foreign
companies are spending billions of dollars to build or expand operations.
In the process, they are lifting local economies and offsetting some of the
jobs being sent offshore by American companies.
[Some] economists say […] that insourced jobs tend to be higher
paying and more stable than the ones moving out of the country. Besides,
they add, were it not for foreign companies buying American companies,
many of those jobs would have vanished.166
Therefore, foreign companies are helping to offset outsourced jobs by providing
higher paying jobs in many of the areas in the United States effected by outsourcing.
162

Id.

163

John Cassidy, Winners and Losers; The Truth About Free Trade, THE NEW YORKER,
Aug. 2, 2004 (“[T]he copyright business, which includes film, music, books, and software,
accounts for about 5 percent of the GDP, which means it is the biggest sector in the economy,
bigger even than the auto industry.”). Id.
164

Bailey & Farrell, supra note 159.

165

Id.

166

Belson, supra note 155.
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A third criticism is that the United States economy suffers, when American
companies outsource. In fact, research indicates that the opposite is true. According
to a 2003 study by the McKinsey Global Institute, outsourcing is directly benefiting
the United States. “For every dollar of corporate spending outsourced to India, the
U.S. economy captures more than three-quarters of the benefits and gains as much as
$1.14 in return.”167 As for more tangible results of outsourcing, consumers are
directly benefiting in the form of lower prices.168 Therefore, research indicates that
outsourcing benefits the U.S. economy.
The debate over outsourcing is actually a debate between public policy experts
and international economists. The public policy experts are looking at the immediate
short-term adverse effects of outsourcing. On the contrary, the economists are
looking at the eventual positive impact that outsourcing has on the American and
other global economies. While the theorists continue to battle over outsourcing in
the marketplace of ideas, Americans need a resolution to important issues like the
rising cost of prescription drugs. For this reason, outsourcing is currently the best
option available.
b. Outsourcing Benefits the Pharmaceutical Industry and India
Outsourcing is a growing phenomenon in U.S. business policies.169 The question
remains whether the multinational pharmaceutical companies can upgrade current
Indian manufacturing facilities, construct new facilities, and have adequate reserve
funds for their own brand-name drugs.170 With the significant investments that have
been made, the pharmaceutical industry is very interested in the results of the
outsourcing debate.171 India provides the pharmaceutical industry with “substantially
lower labor costs” (“50 to 90 percent lower, depending on the position”), a larger
pool of “highly educated technical and professional people,” and a “huge population
for clinical trial subjects.”172 While the multinational companies will have to help
pay for the improvements to the Indian infrastructure, the biggest advantage of doing

167

Bailey & Farrell, supra note 159; see also Hicks, supra note 158. Don Hicks is the
owner of a family-owned and operated car dealership in Colorado and is also the vice
chairman of the American International Auto Dealers Association. Hicks indicates that
competition from international automakers has forced domestic automakers “to improve the
average initial quality of domestic nameplate vehicles” by 32 percent in the last seven years.
Id.
168

Bailey & Farrell, supra note 159.

169
Id. Protectionism is not a feasible option. The federal government and state
governments have been trying to pass legislation to curb outsourcing of American jobs.
Earlier this year, the Senate passed a watered down amendment that prohibited the
government entering into service agreements with foreign contractors. Id. In Ohio, a similar
bill failed when legislators discovered that practically all of its current contractors were
already outsourcing some of their services. Id.
170
Manjeet Kripalani & Pete Engardio, India: Will A Shocking Election Upset End the
Economic Boom?, BUS. WK., May 31, 2004, at 42, 43.
171

Bartlett & Steele, supra note 42.
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Miller, supra note 156.
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business with Indian pharmaceutical companies is cheaper labor and lower
manufacturing costs.173 Moreover, these operational cost savings will eventually
offset the revenue that the multinational companies invested and still provide profits
that can be distributed to shareholders or accumulated for research and development.
Therefore, an alliance with Indian pharmaceutical companies equally benefits the
multinational company and the public who will have access to cheaper generic drugs.
The Indian drug manufacturers will also benefit from this alliance. The Indian
drug manufacturers will learn more about the American standards for drug safety
that they can apply to their domestic manufacturing programs. They will be able to
reduce operational costs because they will have to establish more efficient
production methods that can meet the demands of the international and domestic
markets. Also, as they save more money from their operational expenditures, Indian
drug manufacturers will be able to make more profit from their American drug sales,
which will make them more self-sufficient and enable them to maintain their own
facilities according to FDA-compliant guidelines without depending on loans from
the multinational companies.
Therefore, the multinational pharmaceutical
companies will eventually be able to keep more of their own revenues for costs
related to their brand-name drugs, rather than indefinitely spending their own cash
reserves on the Indian manufacturing facilities.
VI. CONCLUSION
There is a national crisis in the United States. American senior citizens are
spending their hard-earned retirement pension funds on high prescription drug prices.
The FDA and multinational drug companies have hampered American consumers’
efforts to import prescription drugs from Canada. This reality makes a solution to

173
The following is a brief look at the development of Indian outsourcing over the past
decade.
The Indian outsourcing business grew out of a more basic industry providing Indian
computer programming and code-writing expertise to American hardware and
software giants. When Indian firms entered the outsourcing business serving firms of
all sorts, a business then dominated by the likes of IBM and EDS, much lower labour
costs held the key to its rapid revenue growth: over 50% a year in 1994-2001. The
time difference also gave India a selling-point. [T]he ten-hour time gap between
America and India, American clients could offer 24-hour service by switching to
Indian workers during the American night…. Just as the established global
outsourcing firms are increasing their presence in India, so the leading local firms are
becoming more multinational. In part, this is because customers need to be reassured
that outsourced services would not be disrupted by, say, a nasty further deterioration in
political relations between India and Pakistan. Less speculatively, they have been
trying to meet client demands for global outsourcing for 24 hours a day by opening
operations across America, Europe and the Asia-Pacific region…. At some point, the
Indian firms may find themselves facing a choice similar to that now confronting
IBM, EDS and others: move to a lower-cost location or become uncompetitive.
[Currently, India believes that it has] a window of three to five years [of outsourcing
dominance before] China, Russia or the Philippines emerges as a seriously
competitive threat to Indian outsourcing.
America’s Pain, India’s Gain, ECONOMIST, Jan. 11, 2003.
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the prescription drug issue more crucial. Thus, compulsory licensing of necessary
brand-name pharmaceutical patents is the answer that millions of Americans seek.
This article proposes the creation of a tripartite health care commission that will
bring the pharmaceutical industry, the senior citizens’ lobby, and the federal
government together on an equal footing to resolve the high cost of prescription
drugs while providing adequate patent protection for inventors. This article also
proposes that an alliance with Indian pharmaceutical companies will provide cheaper
generic drugs for American senior citizens and will help the multinational drug
companies generate future profits and create a strong relation with India that can help
them with the manufacture of their own brand-name drugs. If these proposals are
enacted, Medicare will finally realize its goal to provide some of the most valuable
members of American society—its senior citizens—fair and equal access to health
care benefits.
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